The aim of this study was to evaluate the diagnostic accuracy of ischemia modified albumin (IMA) alone, or in combination with cardiac troponin T (cTnT) and electrocardiogram (ECG) findings for diagnosis of acute coronary syndrome (ACS). The study included patients with acute chest pain suggestive on ACS, recruited within 6 hours from onset. Patients were classified in ACS group and non-ischemic chest pain group (NICP). Of 84 patients, 49 were diagnosed with ACS and 35 with NICP. IMA was significantly higher in ACS group (p<0.0001). The area under receiver operating curve for IMA in ACS diagnosis was 0.95 (p<0.0001). Sensitivity and specificity of IMA for ACS diagnosis were 89.8% and 91.4%, respectively. IMA significantly (p<0.05) improved the sensitivity of ECG and cTnT, alone, and in combination. Sensitivity and negative predictive value of combination of IMA, ECG and cTnT for diagnosis of ACS were 100%. IMA is useful for diagnosis of ACS, in combination with ECG and cTnT.
Rationale and design of the GRACE (Global Registry of Acute CoronaryEvents) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;190–9.
2.
Hamm C, Bassand J, Agewall S, Bax J, Boersma E, Bueno H. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;2999–3054.
3.
Bar-Or D, Lau E, Winkler J. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia. J Emerg Med. 2000;311–5.
4.
Bertrand M, Simoons M, Fox K, Wallentin L, Chw H, Mc Fadden E. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;1809–40.
5.
Steg P, James S, Atar D, Badano L, Lundqvist C, Borger M. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;2569–619.
6.
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;1–113.
7.
Mccord J. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;159–63.
8.
Cobbe S, Poole-Wilson P. The time of onset and severity of acidosis in myocardial ischemia. J Mol Cell Biol. 1980;745–60.
9.
Berenshtein E, Mayer B, Goldberg C, Kitrossky N, Chevion M. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J Mol Cell Cardiol. 1997;3025–9.
10.
Reimer K, Lowe J, Rasmussen M, Jennings R. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation. 1977;786–94.
11.
Bar-Or D, Winkler J, Vanbenthuysen K, Harris L, Lau E, Hetzel F. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB,myoglobin and troponin I. Am Heart J. 2001;985–91.
12.
Sinha M, Gaze D, Tippins J, Collinson P, Kaski J. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation. 2003;2403–5.
13.
Garrido I, Roy D, Calvino R, Vazquez-Rodriguez J, Aldama G, Sales C, et al. Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am J Cardiol. 2004;88–90.
14.
Sinha M, Roy D, Gaze D, Kaski J. Role of “Ischemia Modified Albumin”, a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emerg Med J. 2004;29–34.
15.
Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, Arroyo-Espliguero R. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol. 2004;297–301.
16.
Hjortshoj S, Kristensen S, Ravkilde J. Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am J Emer Med. 2010;170–6.
17.
Behera S, Mangaraj M, Pch M. Diagnostic efficacy of ischemia modified albumin and its correlation with lipid profile, oxidative stress in acute myocardial infarct patients on admission. Asian Pacific Journal of Tropical Disease. 2012;62–5.
18.
Liyan C, Zh J, Yonghua W, Xiaozhou H. Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal. 2008;45–9.
19.
Abadie J, Blassingame C, Bankson D. Albumin cobalt binding assay to rule out acute coronary syndrome. Ann Clin Lab Sci. 2005;66–72.
20.
Charpentier S, Ducasse J, Cournot M, Maupas-Schwalm F, Elbaz M, Baixas C. Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of non-ST-elevation acute coronary syndrome in the emergency department. Acad Emerg Med. 2010;27–35.
21.
Apple F, Quist H, Otto A, Mathews W, Murakami M. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem. 2002;1097–100.
22.
Senes M, Kazan N, Coskun O, Zengi O, Inan L, Yucel D. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem. 2007;43–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
